Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 0.93 Delayed Data As of Jul 24 |  -0.0349 / -3.62%Today’s Change | 0.75 Today|||52-Week Range 1.42 | +1.09% Year-to-Date |
| BioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session Jul 21 / Zacks.com - Paid Partner Content | BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer Jul 11 / Zacks.com - Paid Partner Content |
| Previous close | 0.96 |
| Today’s open | 0.96 |
| Day’s range | 0.92 - 0.96 |
| Volume | 341,061 |
| Average volume (3 months) | 471,904 |
| Market cap | $92.3M |
| Dividend yield | -- |
| Earnings growth (last year) | -0.36% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 1.57 |
| Today’s change | Today’s % change | |
|---|---|---|
| ARQLArQule Inc | -0.05 | -3.91% |
| LPCNLipocine Inc | +0.20 | +4.25% |
| OPHTOphthotech Corp | -0.05 | -1.90% |
| ARLZAralez Pharmaceutica... | -0.05 | -3.50% |
| Next reporting date | August 10, 2017 |
| EPS forecast (this quarter) | -$0.05 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$15.9M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer & Head-Investor Relations Philip Adam Serlin |
Chief Financial Officer Mali Zeevi |
Corporate headquarters Modi'in, Tel Aviv |
